Articles and Editorials|

SHL shares insights into developing digital solutions for drug delivery systems

B Home Page Bg 800x580

Advances in technology are driving a proliferation of smart connected devices that can store and transmit valuable usage data. In the area of drug delivery, the data can be used to help patient adherence and facilitate communication from patient to health care provider and further.

Combining internal knowledge and experience with active partnerships, SHL has launched a number of initiatives in the digital space for drug delivery systems. The company recently shared its insights in the article “Not Just another Gadget: Insights into Developing Digital Solutions That Work,” which was published in the June 2017 issue of OnDrugDelivery Magazine.

Emphasizing the patient-centric approach to developing connected devices, the article explores the development of digital health by asking the following key questions:

  • Will connected devices be accepted in the real world?
  • Where do we start?
  • How do we create additional value?
  • Who will benefit?

In addressing the questions, the article notes that a connected device should not be treated as “another gadget that will entertain the user for a few months and then be forgotten.” Rather, digital solutions for drug delivery solutions need to be developed with a thoughtful and weighted approach that is aimed at providing both short- and long-term benefits for patients and stakeholders alike.

Read the article in full HERE, or online at ONDrugDelivery.

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News